NMRD

Nemaura Makes “The Announcement”

In a press release this morning, Nemaura Medical (NMRD), a medical technology company focused on diabetes, announced receipt of a material purchase order from its U.K. licensee, DB Ethitronix Ltd. The press release describes the order as being for for 5,000 sugarBEAT® transmitters and 200,000 sugarBEAT® sensors, with an additional rolling monthly purchase order that […]

Read More »

Nemaura Medical Shareholder Update

This morning, Nemaura Medical (NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced a shareholder update call on Wednesday, April 28, at 4:30 pm EST. Participants may pre-register and may also submit questions for management to answer in advance. There will be no […]

Read More »

NMRD Launches App & Begins Pilot Distribution

Today, Nemaura Medical (NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced the launch of its BEATdiabetes app on the GooglePlay and iOS platforms. The interactive app provides predictive information such as smart eating choices, exercise and other potential lifestyle changes over the long […]

Read More »

Nemaura Medical Appoints Advisor on Global Product Manufacture Strategy

Today, Nemaura Medical (NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced the hiring of an industry veteran, Alistair Longmuir, as an Advisor on Global Product Manufacture Strategy. According to the company, Mr. Longmuir “has over 30 Years engineering experience in the fields […]

Read More »

Nemaura Medical Receives Analyst Coverage

Nemaura Medical (NMRD), a medical device company with a non-invasive continuous glucose monitoring (CGM) system, today received its first analyst coverage. Ascendiant Capital rated NMRD as a “Buy” with a $15 price target. NMRD was first covered by Breakout Investors on February 3. Although NMRD is currently “pre-revenue,” they are expected to sign at least […]

Read More »

NMRD With Two Big Hires

Today, Nemaura Medical (NMRD), a medical device company with a non-invasive continuous glucose monitoring (CGM) system, announced the hiring of Thomas Mortensen as head of E.U. commercial operations and marketing. Mr. Mortensen brings with him extensive experience in NMRD’s industry. According to the PR: “Mr. Mortensen has spent more than 25 years in commercialization and […]

Read More »